All In Biotech

NDA 206488 · Sarepta Theraps INC

Exondys 51

Eteplirsen · Intravenous · Antisense Oligonucleotide

NovelAccelerated approvalPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Sep 19, 2016

Approved uses

1

Original approval plus efficacy supplements

Registered trials

11

2 Phase 3, 0 recruiting

FAERS reports

2,414

495 serious, 68 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 13, 2025.

EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. EXONDYS 51 is an antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 )]. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. ( 1 )

Mechanism: Eteplirsen is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. Exon skipping is intended to allow for production of an internally truncated dystrophin protein, which was evaluated in Study 2 and Study 3 [ see Clinical Studies ( 14 ) ].

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Sep 19, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLetterLabelSummary Review
2 products under this application
  • EXONDYS 51 · ETEPLIRSEN 500MG/10ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription
  • EXONDYS 51 · ETEPLIRSEN 100MG/2ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Eteplirsen" as an intervention, any sponsor and status, largest first.

All 11 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product dose omission issue697
  • no adverse event550
  • intentional dose omission279
  • poor venous access187
  • device issue182
  • pyrexia110
  • covid-1987
  • malaise74
  • pneumonia64
  • fall62
  • cough56
  • illness55

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20162
201748
2018223
2019155
2020193
2021255
2022246
2023387
2024340
2025325
2026240

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Exondys-51 (Eteplirsen)

2024 spending

$26.8M

Beneficiaries

18

440 claims

Per beneficiary

$1,488,217

$811.57 per unit

View as table
YearSpending
2020$15,420,573
2021$18,738,226
2022$25,522,809
2023$24,497,663
2024$26,787,913

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 14 on PubMed

Sponsor: Sarepta Theraps INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.